Anti-tumor effects of Atractylenolide I on bladder cancer cells by unknown
RESEARCH Open Access
Anti-tumor effects of Atractylenolide I on
bladder cancer cells
Rui Yu1, Bi-xia Yu2, Jun-feng Chen2, Xiu-yi Lv2, Ze-jun Yan2,3, Yue Cheng2,3* and Qi Ma2,3*
Abstract
Background: Atractylenolide I (ATR-1), an active component of Rhizoma Atractylodis Macrocephalae, possesses
cytotoxicity against various carcinomas. However, little is known about the effects of ATR-1on bladder cancer. In the
present study, the anti-tumor activity of ATR-1 was examined on bladder cancer cells both in vivo and in vitro.
Methods: MTT assay was used to assess the cytotoxic effect of ATR-1. Cell cycle distribution and apoptosis levels
were evaluated using flow cytometry. Western blotting assay was applied to measure the levels of proteins
associated with the apoptotic pathway, cell cycle progression and PI3K/Akt/mTOR signaling pathway. Tumor
models in nude mice were induced by injection of T-24 and 253J human bladder cancer cells.
Results: ATR-1 inhibited bladder cancer cell proliferation, arrested cell cycle in G2/M phase through up-regulation
of p21 and down-regulation of cyclin B1, CDK1 and Cdc25c. Meanwhile, ATR-1 also triggered cellular apoptosis
depending on the activation of mitochondrial apoptotic pathway. Mechanism investigation indicated that ATR-1
exerts its anti-tumor effect also relies on the inhibition of PI3K/Akt/mTOR signaling pathway. Finally, mice studies
showed that ATR-1 blocked the T-24 or 253J-induced xenograft tumor growth without noticeable toxicity.
Conclusions: ATR-1 may be served as a potential therapeutic agent for the treatment of bladder cancer.
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Background
Bladder cancer is the second most common urological
malignancies with an estimated 429,000 new cases and
165,000 deaths every year [1]. Most bladder cancer cases
are superficial and treated with transurethral resection
in the clinic. However, approximately 20 to 25 % of pri-
mary bladder cancers have invaded the muscle layer of
the bladder wall at first diagnosed and radical cystec-
tomy is needed [2]. Current treatments to bladder can-
cer have high recurrence rates and may cause strong
side effects [3]. Although great efforts have been made
in the treatment of bladder cancer over past decades, it
still remains as a major health concern and new thera-
peutic approaches are urgently required [4].
In recent years, natural products have attracted great
attentions for identifying new anti-tumor agents due to
their high efficacy and low toxicity. Atractylenolide
(ATR) can be extracted from Rhizoma Atractylodis
Macrocephalae(RAM) which was used as an herb medi-
cine in eastern Asia for a long history. ATR have three
members named ATR-1, ATR-2 and ATR-3 respectively
(Fig.1a). ATR exhibits a wide range of biological and
pharmacological activities, such as anti-inflammatory,
neuroprotection and gastroprotective effects [5–7].
Among the three members of ATR, ATR-1 exerts the
best anti-tumor activity [8, 9]. For example, ATR-1 was
able to trigger apoptosis and cell cycle arrest in melan-
oma cells as well as lung carcinoma cells in vitro [9, 10].
Meanwhile, ATR-1 could also suppress the growth of lung
cancer in vivo [11]. Notably, a clinical study showed that
ATR-1 treatment on gastric cancer cachexia patients can
improve appetite and KPS (Karnofsky performance status)
with few side effects [12]. These studies indicate that
ATR-1is a promising and safe anti-tumor agent. However,
the effects of ATR-1 on bladder cancer have never been
reported and the mechanisms behind the anti-tumor ac-
tivity of ATR-1 still need further investigation.
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Cancer therapeutics often suppress cancers through
interfering with cell cycle and/or triggering cellular
apoptosis. The cell cycle progression is driven by cyclin-
dependent kinases (CDKs) and cyclins, which act to-
gether to regulate cell cycle transition from G1 to S
phase and/or from G2 to M phase [13]. Cell cycle de-
regulation leading to uncontrolled cell proliferation is
one of the most common alterations during cancer de-
velopment [13]. Therefore, blockage of cell cycle is con-
sidered as an effective cancer therapeutic strategy.
Besides the cell cycle progression, apoptosis process is
another vital target of anti-cancer agents. In eukaryotic
cells, apoptosis can be triggered by two major signaling
pathways: the extrinsic pathway and the intrinsic path-
way which is also known as the mitochondrial pathway.
The mitochondrial pathway is initiated with mitochon-
drial membrane potential (MMP) loss, releases of cyto-
chrome c, lead to the activation of caspases, and
ultimately resulting in chromatin condensation, DNA
fragmentation and the formation of apoptotic bodies
[14]. The mitochondrial pathway is regulated mainly by
the Bcl-2 family members. Bcl-2 family members can be
divided into two groups: pro-apoptotic members like
Bax, Bad, and anti-apoptotic members like Bcl-2, Bcl-xl,
Mcl-1 etc. Cancer cells often evade apoptosis due to the
down-regulation of pro-apoptotic Bcl-2 proteins and/or
Fig. 1 Effects of ATR-1 on the viability of bladder cancer cells. a Chemical structure of ATR-1, ATR-2 and ATR-3. b Bladder cancer cell lines RT4, 5637, T-24
and 253J, were treated with ATR-1 with different concentrations for 48 h. c T-24 and d 253J cells were treated by various concentrations of ATR-1 for
24 h, 48 h and 72 h. Cell viability determined by MTT assay as described in Methods section. Data represent mean ± S.D. (n =3)
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up-regulation of anti-apoptotic Bcl-2 proteins. There-
fore, agents with inhibitory activities toward anti-
apoptotic Bcl-2 members may be valuable to fight
against cancers.
Plenty of studies have confirmed that PI3K/Akt/
mTOR signaling pathway is often constitutively activated
and plays an important role in the development of vari-
ous cancer types and resistance to anticancer therapies
[15, 16]. Particularly, the PI3K/Akt/mTOR pathway was
also found to be associated with a substantial number of
bladder cancers. Amplification and/or mutations of sev-
eral key genes regulating this pathway, such as PIK3CA
(encoding the p110α subunit), PIK3R1(encoding the
p85α subunit), AKT, and PTEN, are well-known mecha-
nisms involved in the activation of PI3K/Akt/mTOR
pathway in bladder cancer [17]. Moreover, inhibitors of
the PI3K/Akt/mTOR pathway showed promising results
in preclinical studies. For example, an inhibitor named
RAD001 or everolimus could significantly inhibit the
growth of bladder tumor both in vitro and in vivo [18].
Therefore, targeting PI3K/Akt/mTOR might be an ef-
fective strategy in the treatment of bladder cancer.
In the present study we investigated the anti-tumor ac-
tivity of ATR-1on human bladder cancer cells and ex-
plored the underlying molecule mechanisms. We found
ATR-1 inhibited bladder cancer cell proliferation,
arrested cell cycle in G2/M phase, induced apoptosis
through the mitochondrial pathway, and blocked the
PI3K/Akt/mTOR pathway. Furthermore, ATR-1 sup-
pressed xenograft bladder cancer growth in vivo. Thus,
ATR-1 is a valuable natural product that may play a role
in clinical usage for the treatment of bladder cancer.
Methods
Reagents and antibodies
ATR-1, Z-DEVD-fmk (caspase-3 inhibitor), Z-LEHD-fmk
(caspase-9 inhibitor), 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazoliumbromide (MTT) and all other chemicals
were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Antibodies against AKT, p-AKT, and PI3K were
from Abcam Inc. (Cambridge, UK). Antibodies against
CDK1, cyclin B1, Bax (6A7), mTOR, PTEN and p21 were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Antibodies against caspase-9, caspase-3, Bcl-2,
Mcl-1, Bcl-xl, Bad, Bax, Bak, Cytochrome-c, Smac/Diablo,
Cox-IV, cdc25c, p-Cdc25cand β-actin were from Cellular
Signaling Technology (Danvers, MA, USA).
Cell culture and transfection
The bladder cancer cell lines were obtained from the
Cell Resource Center, Shanghai Institute of Life Sciences,
Chinese Academy of Sciences (Shanghai, China). The
cell lines were cultured in RPMI 1640 media supplemented
with 10 % fetal bovine serum, penicillin (100 U/mL) and
streptomycin (100 μg/mL) on 37 °C with 5 % CO2. RPMI-
1640 medium and fetal bovine serum (FBS) were pur-
chased from Thermo Scientific (Rockford, USA). Penicillin
and streptomycin were purchased from Gibco BRL, Invi-
trogen (Carsbad, CA, USA). All cells were split every 3 days
and seeded at 1 × 105 cells/ml onto plate 24 h before each
experiment. For transfection studies, cells were transiently
transfected with myr-AKT1 plasmid (constitutive active
mutant) or the EGFP (control) plasmid with Fugene HD
(Roche, Switzerland). The myr-AKT1 (#20422) plasmid
was obtained from Addgene Company and EGFP plasmid
was a generous gift from Dr. Hui Liu (Bengbu Medical Col-
lege, Anhui, China). Bax siRNA or scramble siRNA were
synthesized from Life Technologies (Shanghai, China) and
transfected into cells using Lipofectamine 2000(Life Tech-
nologies, Shanghai, China) according to the manufacturer’s
protocol. The sequence of Bax siRNA beginning at nucleo-
tide 187 of the Bax gene, 5-′CTCCGGCGAATTGGA
GATGAA-3′; Total cell lysates were harvested 48 h after
transfection to assess the knockdown efficiency by western
blot analysis.
MTT assay
We used the MTT assay with minor modifications to
measure cytotoxic activity of ATR-1 to different cells
lines of bladder cancer cells [19]. The cells were seeded
in 96-well plates (Corning, NY) with a density of 2 ×
104/well. When reaching 75–80 % confluence, the cells
were exposed to DMSO (0.1 %) or different concentra-
tions of ATR-1, which was dissolved in 0.1 % DMSO.
Two days later, 25 μl MTT (Sigma, St. Louis, MO, USA)
was added to the cultured media, and was removed at
4 h before the end of study. Finally, another 150 μl
DMSO was added to each well, and the absorbance was
measured by ELx800 ELISA Microwell Reader (BioTek
Co, USA). The inhibitory IC50 values of ATR-1were cal-
culated from the dose–response curves fitted by Graph-
Pad Prism software (GraphPad Prism 5.01, GraphPad
Software, Inc., CA, USA). The results were represented
by mean values of three independent experiments.
Apoptosis analysis
To detect apoptosis, cells were incubated with DMSO
(0.1 %) or ATR-1 at different concentrations for 24 h.
The cells were harvested, washed twice with cold 1 ×
PBS. The cells were then stained with FITC Annexin V
Apoptosis Detection Kit (BD Biosciences) according to the
manufacturer’s instruction and subjected to analysis by
flow cytometry (FACScan, Becton-Dickinson, NJ, USA).
The apoptosis was evaluated based on the percentage of
cells with Annexin V+/PI+. The results were indicated as
mean values from three independent determinations. The
results were analyzed by Flowjo software. Five independent
tests with the same conditions were performed.
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Western blotting analysis and immunoprecipitation
Western blot analysis was performed to measure the ex-
pression levels of various proteins in cells. Cells were
treated with different concentrations of ATR-1 for 24 h.
Cells were harvested, washed with cold 1 × PBS, and lysed
with CHAPS lysis buffer (Cellular Signaling Technology,
USA) for 30 min on ice, then centrifuged at 12,000 g for
15 min at 4 °C.The protein concentrations were measured
by BCA protein assay kits (Sigma Aldrich, Saint Louis,
Missouri, USA). Equal quantities of protein were loaded
and separated by 12 % SDS-PAGE, and then transferred to
a PVDF membrane (Millipore Inc. MA, USA). The blots
were blocked in 12 % non-fat milk or 5 % BSA, and incu-
bated with primary antibodies, followed by incubation with
secondary antibodies conjugated with horseradish peroxid-
ase (HRP). Ultimately, the protein bands were visualized
by enhanced chemiluminescent reagents (Thermo scien-
tific, Rockford, USA). For Bax immunoprecipitation, equal
amounts of protein from whole cell lysates (800 μg) were
used for immunoprecipitation. All samples were brought
to a final volume of 450 μl with CHAPS lysis buffer (1 %
CHAPS, 10 mM Hepes pH 7.4, 150 mM NaCl, and prote-
ase inhibitors). Samples were then rotated for 5 h at 4 °C
with 5 μl of monoclonal antibodies (Bax 6A7, 200 μg/ml)
and 150 μl anti-rabbit IgG magnetic beads. Then beads
were precipitated by a magnetic field and washed five
times with CHAPS buffer. Finally, the last supernatant was
removed and 25 μl of 5 × loading buffer added. The beads
were incubated in the loading buffer at 95–100 °C for
5 min, and then centrifuged at 12,000 rpm for 5 min. The
supernatants were subjected to Western blotting analysis.
Preparation of subcellular fractions
In order to separate the cytosolic and mitochondria frac-
tions, cells were washed in ice-cold PBS. The cells were
then lysed using CLAMI (Cell Lysis and Mitochondria
Intact) buffer (250 mM Sucrose, 80 mM KCl, 50 μg/ml
Digitonin in PBS) on ice for 5 min, and the cell suspen-
sion was centrifuged at 1500 rpm for 5 min at 4 °C. The
supernatant was removed and stored at−20 °C as the
cytosolic fraction.
Cell cycle analysis
Cell cycle status was detected by flow cytometry and an-
alyzed by Flowjo software. Briefly, cells were seeded onto
6-well plates at a density of 1 × 106 cells/well and incu-
bated for one day. After treatment with various concen-
trations of ATR-1 for 24 h, the cells were then harvested
and washed with 1× PBS. Cell pellets were fixed in 70 %
cold ethanol overnight. The fixed cells were resuspended
in 1 × PBS containing 1 mg/ml RNase A (Sigma-Aldrich,
USA), incubated for 1 h at 37 °C, and the cells were
stained by adding 50 μg/ml PI (Sigma-Aldrich, USA) for
30 min at room temperature in the dark. The cells were
then analyzed using flow cytometry (FACScan, Becton-
Dickinson, NJ, USA). The results were indicated as mean
values from three independent determinations.
Tumor xenograft model
The animal study was approved by Ethical Committee on
Animal Research of Ningbo University. Four week old
male BALB/c nude mice were purchased from the Shang-
hai Laboratory Animal Center, Shanghai Institute for Life
Sciences, Chinese Academy of Sciences (Shanghai, China).
To induce tumors in nude mice, cell lines were harvested
and suspended in RPMI-1640 medium. Then the tumor
was prepared by injection of 5 × 106 cells at right area of
nude mice. When the size of tumors reached to 6–9 mm
in diameter, the tumor-bearing mice were randomly di-
vided into control and treated groups (8–9 mice for each
group), which received intraperitoneal administration of
DMSO (0.1 %) or ATR-1(25, 50, 75 mg/kg/day) for
4 weeks. Meanwhile, the sizes of tumor were periodically
measured by calipers, and the volume was obtained by fol-
lowing formula: tumor volume (mm3) =maximal length
(mm) × (perpendicular width) (mm)2/2. At the end of
study, the mice were killed, and the tumors were removed
for further measurement of weight.
Statistical analysis
SPSS software (version 12; SPSS Inc., Chicago, IL, USA)
was used for statistical analysis. Data are presented as
the mean ± the standard deviation. Differences between
groups were analyzed using the one-way ANOVA and
Student’s t-test. A difference was considered significant
at P < 0.05.
Results
ATR-1 suppresses proliferation of bladder cancer cells lines
The anti-proliferative activity of ATR-1 was initially eval-
uated by using four human bladder cancer cell lines
RT4, 5637, 253J and T-24. Cells were exposed to various
concentrations of ATR-1 for 48 h, and the cell viabilities
were measured by MTT assay. As shown in Fig. 1b,
ATR-1 inhibited the proliferation of RT4, 5637, 253J and
T-24 in a dose-dependent manner. Accordingly, IC50
values of ATR-1 were determined as 44.5, 18.4, 63.7 and
12.8 μM, respectively (Table 1). We noticed that the pro-
liferation of T-24 and 253J were also reduced by ATR-1
treatment in a time-dependent pattern (Fig. 1c, d).
ATR-1 induces cell cycle arrest at the G2/M phase
Anti-tumor chemicals can often inhibit cell proliferation
through induction of cell cycle arrest. In order to exam-
ine whether the inhibition caused by ATR-1 was a result
of cell cycle arrest, the DNA-based cell cycle was ana-
lyzed by flow cytometry. Firstly, we incubated cells with
various concentrations of ATR-1 for 24 h and then
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examined the DNA content using propidium iodide (PI)
staining. We found that the cell population of ATR-1-
treated T-24 and 253J cells was dose-dependently in-
creased in the G2/M and decreased in the S phase, when
compared with the control cells which were treated with
DMSO (0.1 %) (Fig. 2a, b, c). These results indicate that
the inhibitory effect of ATR-1 on T-24 and 253J bladder
cancer cell proliferation through accumulating G2/M
phase population. Moreover, we tested the effect of ATR-1
on cell cycle checkpoint molecules including cyclin A,
cyclin B1, CDK1,CDK2 and p21 by Western blotting.
Treatment of cells with ATR-1 dose-dependently in-
creased the expression of p21 while down-regulated cyclin
A, cyclin B1, CDK1 and CDK2 in both cell lines (Fig. 2d).
These results suggest that the G2/M cell cycle arrest
induced by ATR-1 may be related with up-regulation of
the cell cycle inhibitory proteins and down-regulation of
the cell cycle transition-promoting proteins.
ATR-1 treatment induced apoptosis in bladder cancer cells
To further study the anti-tumor activity of ATR-1, we
tested whether ATR-1 induces apoptosis in 253J and T-
24 cells. We firstly treated cells with ATR-1 at various
concentrations for 24 h, and then stained the cells with
Annexin V-FITC/PI and measured the proportion of
Annexin V/PI positive cells by flow cytometry. As shown
in the Fig. 3a and b, ATR-1 was able to induce apoptosis
in a dose-dependent manner in both the 253J and T-24
cells. We also performed Western blot to detect caspases
activation, results showed that cleaved fragments of
caspase-9 as well as caspase-3 were found (Fig. 3c). To gain
insight into the role of caspases in the process of ATR-1 in-
duced apoptosis, 253J and T-24 cells were pretreated with
specific caspase inhibitors for caspase-9 and caspase-3 (Z-
LEHD-FMK and Z-DEVE-FMK, 20 μM, respectively) for
1 h and then incubated with ATR-1 for 24 h. The apoptosis
assay revealed significantly reduced apoptosis in the cells
pretreated with caspase-9 and caspase-3 inhibitor (Fig. 3d).
These results indicate that ATR-1 may induce apoptosis
through the intrinsic pathway.
Fig. 2 ATR-1 suppressed cell cycle progression in bladder cancer cells. a Representative flow cytometry profiles of cell cycle distribution after treatment
with DMSO (0.1 %) or various concentrations of ATR-1 for 24 h. b & c Quantitative analysis of cell cycle distribution of 253J (b), and T-24 (c) cells treated
with DMSO (0.1 %) or indicated concentrations of ATR-1. d 253J (right) and T-24 (left) cells were treated with various concentrations of ATR-1 for 24 h,
whole cell lysates were analyzed by Western blotting, β-Actin was used as a loading control. Data represent mean ± S.D. (n =3).*p < 0.05, **p < 0.01
Table 1 IC50 values of bladder cancer cell lines treated with ATR-1
for 48 h
Cell lines IC50 values (μM)
T-24 12.8 ± 2.6
5637 18.4 ± 3.1
RT4 44.5 ± 5.3
253J 63.7 ± 7.4
Data represent mean ± S.D. (n = 3)
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ATR-1 induces cell apoptosis through mitochondrial pathway
In order to further test whether ATR-1 induces apop-
tosis through the activation of mitochondrial apoptotic
pathway, we detected several proteins involved in this
pathway. After the treatment of various concentrations
of ATR-1 on bladder cancer cells for 24 h, we measured
the levels of Bcl-2 family members. As shown in Fig. 4a,
the expression levels of anti-apoptotic proteins Bcl-2,
Mcl-1 and Bcl-xl were significantly decreased, but pro-
apoptotic proteins Bad and Bax were increased while
Bak was not affected. In addition, ATR-1 can cause Bax
activation (Fig. 4b, upper) and release of cytochrome c
and Smac/Diablo into cytosol (Fig. 4b, lower). Moreover,
we used siRNA to silence Bax in T-24 and 253J cells
(Fig. 4c). The apoptosis induced by ATR-1 and cleavage
of caspase-3 were significantly attenuated by silencing of
Bax in both cells when compared with control cells that
were transfected with scramble siRNA (Fig. 4c and d).
Taken together, these results confirm that ATR-1 in-
duces apoptosis in human bladder cancer cells through
mitochondrial apoptotic pathway.
ATR-1 treatment down-regulated PI3K-Akt-mTOR signaling
pathway in vitro
It is well documented that constitutive activation of
PI3K-Akt-mTOR signaling pathway, which contributes
to the development of bladder cancer, can also lead to
the down-regulation of Bad [17, 20, 21]. Since ATR-1
treatment results in the up-regulation of Bad (Fig. 4a),
we hypothesized that PI3K-Akt-mTOR may be involved
in the ATR-1 mediated anti-tumor effects. As shown in
Fig. 5a, ATR-1 significantly inhibits the phosphorylation
of AKT at Ser473 as well as the expression of mTOR, a
known downstream target of AKT, in a concentration
dependent manner (Fig. 5a). At the same time, there
were no changes of the expression of main subunit of
Fig. 3 ATR-1 induces apoptosis in bladder cancer cells. a Representative flow cytometry profiles of apoptosis induced by different concentrations
of ATR-1 in 253J (upper) and T-24 (lower) cells. b Quantitative results obtained using Annexin V/PI staining. c Western blot analysis of apoptosis-related
caspases proteins, β-Actin was used as an equal loading control. d Pretreatment of Z-LEHD-FMK, and Z-DEVE-FMK inhibits the apoptosis triggered by
ATR-1. Data represent mean ± S.D. (n =3).*p < 0.05, **p < 0.01
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PI3K like p110-α and total AKT (Fig. 5a). Moreover,
treatment of 253J and T-24 cells with ATR-1 resulted in an
increased expression of PTEN, a key negative regulator of
PI3K pathway (Fig. 5a). In order to further elucidate the
role of PI3K-Akt-mTOR pathway, we transfected 253J and
T-24 cells with a plasmid encoding constitutively active
AKT1 (myr-AKT1) or EGFP plasmid, 12 h after the trans-
fection we treated the cells with ATR-1 for another 48 h
and measured the cells viability. As shown in Fig. 5b-d,
over-expression of myr-AKT1 could noticeably rescued the
anti-proliferative effect of ATR-1. At the same time, we also
measured the levels of Bax and Bad in cells overexpressed
of myr-AKT1 to investigate the association between AKT
activation and these pro-apoptotic proteins. The western
blotting results showed that activation of AKT led to
reduction of ATR-1-induced up-regulation of Bax and
Bad compared with EGFP-transfected control cells
(Fig. 5b). In summary, these data suggest that ATR-1
exerts its anti-tumor function, at least partially, through
interfere with the PI3K/AKT/mTOR signaling pathway,
which may result in cellular apoptosis in the end.
Anti-tumor effects of ATR-1 in vivo
We then assessed anti-tumor effects of ATR-1 in mouse
model. Xenograft tumors were induced by subcutaneous
injections of T-24 cells or 253J cells in female BALB/C
nude mice. After solid tumor size reached to 100 mm3,
mice were randomly divided into four groups and ad-
ministrated with either DMSO (0.1 %) or 25 mg/kg,
50 mg/kg, and 75 mg/kg of ATR-1 once every four days.
As shown in Fig. 6a-c, when compared with mice treated
with vehicle, mice treated with ATR-1 appeared with re-
duction of tumor volume as well as tumor weight in
vivo. Notably, there were no any significant difference of
body weights between vehicle treated and ATR-1 treated
mice, indicating that ATR-1 can be well tolerant. To-
gether, the results demonstrate that ATR-1 inhibits both
xenografted T24 and 253J cells in vivo.
Discussion
ATR-1, an active constituent of Rhizoma Atractylodis
Macrocephalae, has been shown to have anti-tumor ac-
tivity though its potential mechanisms are still elusive.
In the present study, we found ATR-1 exhibited dose-
dependent anti-tumor effects on human bladder cancer
cells such as causing cell cycle arrest, inducing apop-
tosis and inhibition of PI3K/Akt/mTOR signaling
pathway.
Unregulated cell cycle is often considered as one of
the major characteristics in cancers. Anti-tumor agents
Fig. 4 ATR-1 induces apoptosis mainly through the mitochondrial pathway. aWestern blot analysis of apoptosis-related proteins. b ATR-1 treatment can lead
to activation of Bax (upper) and release of cytochrome-c (cyto c) and Smac/Diablo into cytosol (lower). c Silencing of Bax by specific siRNA can inhibit the
activation of caspase-3. d Down-regulation of Bax significantly attenuates ATR-1-induced apoptosis. Data represent mean ± S.D. (n =3).*p< 0.05, **p< 0.01
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Fig. 6 ATR-1 suppressed the growth of bladder cancer in nude mice. a Tumor volume changes in T-24 (left) and 253J (right) group after ATR-1
treatment. b Tumor weight changes in T-24 (left) and 253J (right) group after ATR-1 treatment. c Tumor masses of each group. d Body weight
changes of each group. Data represent mean ± S.D. (n = 6–8). *p < 0.05, **p < 0.01 compared to model group
Fig. 5 ATR-1 suppressed PI3K/AKT/mTOR signaling pathway. a Suppression of phosphorylated AKTSer473, mTOR and induction of PTEN by ATR-1
in 253J (left) and T-24 (right) cells. β-Actin was used as an equal loading control. b Analysis of cells transfected with AKT1 constitutively active
plasmid or EGFP plasmid (control). Constitutively active AKT1 inhibited the ATR-1 induced up-regulation of Bax and Bad. c & d Introduction of
constitutively active AKT1 significantly blocks the anti-proliferation activity of ATR-1. Data represent mean ± S.D. (n =3).*p < 0.05, **p < 0.01
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often exert their activities through induction of cell cycle
arrest. It was well recognized that many cancer cells de-
pend on G2 checkpoint more than normal cells due to
defective G1 checkpoint during cell replication [19, 22].
Cell cycle progression is regulated by cyclin-dependent
kinases (CDKs) and its regulatory cyclins. The formation
of complex CDK1/cyclin B1 is important for the G2/M
phase transition of cell cycle. Activation of CDK1 re-
quires the specific phosphatase Cdc25, which dephos-
phorylate CDK1 at positions Thr14 and Tyr15, thereby
permitting cell entry into the M phase [23]. In our study,
we found that treatment of ATR-1 leads to the G2/M arrest
in 253J and T-24 cells (Fig. 2a, b, c), which is accompanied
by the down-regulation of cyclin A, cyclin B1, CDK1
and CDK2 whereas increased the level of p21 (Fig. 2d).
In a recent paper, Ye et al. reported that ATR-1 in-
duced cell cycle arrest at G1 phase in melanoma cells
[10]. The discrepancy may be caused by difference of
cell types, and the exact mechanism require further
investigation.
Plenty of studies have proven that the activation of the
apoptotic pathway in cancer cells is a defensive mechanism
against the progression and development of tumor. In the
past years, many compounds have been found to promote
apoptosis by triggering mitochondrial pathway, such as
isoorientin, arsenic trioxide and quinazolinone-chalcone
derivative [24–26]. In the mitochondrial apoptotic path-
way, mitochondrial membrane permeabilization is tightly
regulated by the interaction of pro- and anti- apoptotic
members of Bcl-2 family [27]. The ratio between anti- and
pro-apoptotic Bcl-2 family members has been known as a
determination whether a cell will undergoes apoptosis
[27]. The mitochondrial permeability can be enhanced by
the activation of Bax and formation of channels in the
membrane, which resulted in the release of cytochrome c
and Smac/Diablo [27]. Release of cytochrome c and Smac/
Diablo then led to the activation of caspase-9, caspase-3
and finally apoptosis. Our results showed that treatment of
bladder cancer cells 253J and T-24 led to the increase of
cleaved caspase-9 and caspase-3 (Fig. 3c). We also detected
the release of cytochrome c, Smac/Diablo into cytosol and
activation of Bax (Fig. 4b). Meanwhile, the levels of pro-
apoptotic Bcl-2 members Bax, Bad were increased and
anti-apoptotic Bcl-2, Bcl-xl, Mcl-1were decreased (Fig. 4a).
The use of caspase-9, caspase-3 inhibitors significantly
blocked the ATR-1 induced apoptosis (Fig. 3d). Similarly,
silencing of Bax by specific siRNA also inhibited the apop-
tosis as well as the caspase-3 activation (Fig. 4c, d). This
implicats that Bax was critically involved in ATR-1 induced
apoptosis and highlights the link between PI3K/Akt/
mTOR and Bax. Taken together, these data indicate
that ATR-1-induced apoptosis in human bladder can-
cer cells is dependent on activation of mitochondrial
apoptotic pathway.
Currently, there are three known classes of PI3 kinases
including classes I, II and III, which are classified by
structure and function. The class I PI3K, which has four
isoforms (PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ), is the most
studied isoform in human cancers [28]. AKT, a down-
stream effector of PI3K, has three isoforms: Akt1, Akt2
and Akt3. mTOR is another downstream effector of
PI3K and involved in several cellular activities such as
protein synthesis, translation initiation, cell mass, etc
[15, 29]. PI3K/Akt/mTOR pathway is vital for cancer cell
survival, motility, metabolism, migration and drug resist-
ance. It is estimated that approximately 40 % of urothelial
carcinomas have PI3K/Akt/mTOR pathway activating
mutations [1, 30]. Activation of PI3K/Akt/mTOR also
contribute to the migration, invasion and chemoresistance
of bladder cancer [31, 32]. In our study, western blotting
analysis indicates that phosphorylation of Akt at Ser473
position was decreased by ATR-1 treatment in both blad-
der cancer cell lines in vitro (Fig. 5a). Meanwhile, transfec-
tion of cells with constitutively active Akt1 greatly blocked
the inhibitory effect of ATR-1 (Fig. 5c, d) as well as the
up-regulation of Bax and Bad (Fig. 5b), thereby proving
that the anti-tumor effect of ATR-1 relies on the inhibition
of PI3K/Akt/mTOR pathway. In addition, we also ob-
served increase of expression of PTEN after ATR-1 treat-
ment (Fig. 5a). PTEN is a lipid phosphatase that directly
antagonises the activity of PI3K [28]. Loss or down-
regulation of PTEN represents one of the most common
alterations in bladder carcinoma [17]. These data indi-
cated that the PI3K/Akt/mTOR pathway was involved in
apoptosis induced by ATR-1.
To our knowledge, ATR-1 has several merits that may
facilitate its usage in the future. First, clinic evidences sug-
gest that ATR-1 is safe and low toxic without serious ad-
verse reactions after taken by patients [12]. Second, a
recent work reported ATR-1 sensitized human ovarian
cancer cells to paclitaxel, which indicates the combination
of ATR-1 with current chemotherapeutics may overcome
drug resistance [33]. Third, active components in RAM
were supposed to have immune-enhance activity as one
recent study found extracts from RAM significantly en-
hanced T lymphocyte proliferation individually or syner-
gistically [34]. Thus, ATR-1 is a valuable natural product
which may play a role in the treatment of bladder
cancer individually or in combination with other che-
motherapeutic reagents. Further studies need to be
carried out to investigate ATR-1 therapeutic value in
bladder cancer.
Conclusions
In summary, we have tested the potential therapeutic func-
tion of ATR-1 on two human bladder cancer cell lines in
vitro and in vivo. ATR-1suppresses xenograft tumor
growth, triggers G2/M cell cycle arrest, induces apoptosis
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through intrinsic pathway and blocks PI3K/Akt/mTOR
signaling pathway. Thereby, ATR-1 may be developed as
an effective agent to treat human bladder cancer by further
investigation.
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